Dexmedetomidine use in palliative care patients with intractable symptoms: A retrospective review


Shi-Yuan Yu, B.Sc., Pharm.D.; Jacqueline Schellenberg, B.Sc.(Pharm), Pharm.D.; Alison Alleyne, B.Sc.Phm, Pharm.D.

- results in deep sedation.
- loved ones.

- dexmedetomidine.
- in palliative patients
- dexmedetomidine







	50 (± 13)		
	60		
	59 (± 16)		
	28 (± 12)		
	106 (±13)		
	119 (±26)		
	74 (±12)		
(mode)	30		
	30		
	25		
	25		
	15		
	5		
	90		
	30		
	25		
	15		
	95		
	5		
8.	7 (± 4.8)		
0.19 (± 0.05)			
1.07 (± 0.29)			
0.86 (± 0.44)			
	80		
	5		
	15		
d Scores Da	av 0 - 7		
	—Patient 1		
	-Patient 4		

		—Patient 1
		—Patient 4
		-Patient 5
		-Patient 8
		—Patient 14
		—Patient 16
		—Patient 17
Day 5	Day 6	Day 7

	—Patient 9
	—Patient 10
	—Patient 15
	-Patient 18
	—Patient 19
	—Patient 20
ay 10 Day 11 Day 12 Day 1	3 Day 14

Patients with Incidence (n=20)	Number of Episodes (Mean ± SD)	Hours to 1 st Incidence of Side Effect (Mean ± SD)
17	2.1 (± 1.3)	40 (± 59.1)
2	2.5 (± 0.7)	10.9 (± 12.2)
2	1 (± 0)	26.9 (± 5.8)
7	1.5 (±1.3)	46.3 (± 78.7)
3	2.7 (±2.9)	17 (± 9.1)
-	Incidence (n=20) 17 2 2 7	Incidence (n=20)(Mean \pm SD)172.1 (\pm 1.3)22.5 (\pm 0.7)21 (\pm 0)71.5 (\pm 1.3)

Results

- For PRN medications started before dexmedetomidine and continued throughout, the overall usage of these medications were:
 - 41% reduction, 47% increase, 12% same
- For regularly scheduled medications started before dexmedetomidine and continued throughout, the overall usage of these medications were:
 - 3% reduction, 35% increase, 62% same
- PRN medications had a net increase of 4 orders added (5%) while regular medications had a net increase of 16 orders added (22%)
- 45% of patients had ≥50% of days with RASS 0 to -2 (correlates to rousable) sedation; score of 0 indicates patient is alert and calm, score of -2 indicates light sedation but briefly awakens to voice for <10 second
- 55% of patients had a new initiation of midazolam CSCI while on dexmedetomidine

Limitations

- Retrospective design
- Some data points hard to collect as based on subjectivity of the recorder
- Incomplete results due to limited and inconsistent documentation

Conclusions

- allowing patient to remain sedated but rousable
- Initial decrease in delirium symptoms Despite clinical deterioration, only 47% of PRN medication usage and 35% of
- regularly scheduled medication usage was increased
- On average, CSCI tolerated for > 8 days



Small sample size; patients had varied length of stay and clinical course

Dexmedetomidine provided benefit in managing intractable pain symptoms while

* References available upon request